Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)

US7351411B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Jocelyn Holash · Yonkers, US
• Jesse M. Cedarbaum · Larchmont, US
• John Rudge · Mahopac, US
• George D. Yancopoulos · Elmhurst, US
• Neil Stahl · Carmel, US

Key dates

• Filing date: Mar 10, 2006
• Grant date: Apr 1, 2008
• Expiry date: Aug 16, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia, increasing hematocrit levels, and increasing or stimulating erythropoietin, particularly in subjects being treated for cancer with chemotherapeutic agents and/or radiation.